Common Contracts
5 similar Change in Control and Severance Agreement contracts by Intuity Medical, Inc.
INTUITY MEDICAL, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • September 17th, 2021 • Intuity Medical, Inc. • In vitro & in vivo diagnostic substances • California
This Change in Control and Severance Agreement (the “Agreement”) is made and entered into by and between Timothy Buskey (“Executive”) and Intuity Medical, Inc. (the “Company”), effective as of immediately prior to the time the Company’s registration statement relating to the initial public offering of the Company’s common stock (the “IPO”) becomes effective (the “Effective Date”). This Agreement amends and restates and supersedes in its entirety that certain Change of Control Severance Agreement between Executive and the Company dated as of October 5, 2018 and supersedes the offer letter agreement between Executive and the Company dated as of January 21, 2018 (together, the “Prior Agreements”).
INTUITY MEDICAL, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • September 17th, 2021 • Intuity Medical, Inc. • In vitro & in vivo diagnostic substances • California
This Change in Control and Severance Agreement (the “Agreement”) is made and entered into by and between Dean Zikria (“Executive”) and Intuity Medical, Inc. (the “Company”), effective as of immediately prior to the time the Company’s registration statement relating to the initial public offering of the Company’s common stock (the “IPO”) becomes effective (the “Effective Date”). This Agreement supersedes the offer letter agreement between Executive and the Company dated as of May 25, 2021 (together, the “Prior Agreements”).
INTUITY MEDICAL, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • September 17th, 2021 • Intuity Medical, Inc. • In vitro & in vivo diagnostic substances • California
This Change in Control and Severance Agreement (the “Agreement”) is made and entered into by and between Robb Hesley (“Executive”) and Intuity Medical, Inc. (the “Company”), effective as of immediately prior to the time the Company’s registration statement relating to the initial public offering of the Company’s common stock (the “IPO”) becomes effective (the “Effective Date”). This Agreement amends and restates and supersedes in its entirety that certain Change of Control Severance Agreement between Executive and the Company dated as of March 11, 2015 and supersedes the offer letter agreement between Executive and the Company dated as of October 11, 2011 (together, the “Prior Agreements”).
INTUITY MEDICAL, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • September 17th, 2021 • Intuity Medical, Inc. • In vitro & in vivo diagnostic substances • California
This Change in Control and Severance Agreement (the “Agreement”) is made and entered into by and between Emory V. Anderson (“Executive”) and Intuity Medical, Inc. (the “Company”), effective as of immediately prior to the time the Company’s registration statement relating to the initial public offering of the Company’s common stock (the “IPO”) becomes effective (the “Effective Date”). This Agreement amends and restates and supersedes in its entirety that certain Amended and Restated Change of Control Severance Agreement between Executive and the Company dated as of August 26, 2013 and supersedes the offer letter agreement between Executive and the Company dated as of March 19, 2015 (together, the “Prior Agreements”).
INTUITY MEDICAL, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • September 17th, 2021 • Intuity Medical, Inc. • In vitro & in vivo diagnostic substances • California
This Change in Control and Severance Agreement (the “Agreement”) is made and entered into by and between Tammy Cameron (“Executive”) and Intuity Medical, Inc. (the “Company”), effective as of immediately prior to the time the Company’s registration statement relating to the initial public offering of the Company’s common stock (the “IPO”) becomes effective (the “Effective Date”). This Agreement amends and restates and supersedes in its entirety that certain Change of Control Severance Agreement between Executive and the Company dated as of October 5, 2018 and supersedes the offer letter agreement between Executive and the Company dated as of May 24, 2018 (together, the “Prior Agreements”).
